Format

Send to

Choose Destination
Expert Rev Anti Infect Ther. 2008 Dec;6(6):805-24. doi: 10.1586/14787210.6.6.805.

Cefepime: a reappraisal in an era of increasing antimicrobial resistance.

Author information

1
Department of Medicine, Section of Infectious Diseases, Case Western Reserve University, School of Medicine, Cleveland, OH, USA. aendimiani@gmail.com

Abstract

Cefepime is a 'fourth-generation' cephalosporin with an in vitro extended-spectrum of activity against Gram-negative and Gram-positive pathogens. Cefepime is approved for the treatment of moderate-to-severe infections, such as pneumonia, uncomplicated and complicated urinary tract infections, skin and soft-tissue infections, intra-abdominal infections and febrile neutropenia. In this article, we provide a critical review of pharmacodynamics, clinical management, pharmacokinetics, metabolism, pharmacodynamic target analyses, clinical efficacy, safety and tolerability of cefepime after more than a decade of clinical use.

PMID:
19053894
PMCID:
PMC2633657
DOI:
10.1586/14787210.6.6.805
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Taylor & Francis Icon for PubMed Central
Loading ...
Support Center